LakeShore Biopharma Co., Ltd
Delisted (Nasdaq: YS): renamed LakeShore Biopharma, taken private 2026-06-24
Assets
(2 total)
2Total Assets
0Approved
1Phase 3 / Filed
1Phase 1–2 / Early
2Diseases
Quick filter:
| Target & Modality | |||
|---|---|---|---|
| Phase 3 | Rabies virus antigens (poly I:C-based adjuvant)Vaccine | Infectious Disease Rabies Prevention and Post-Exposure Prophylaxis | |
YS-ON-001No recent activity | Phase 1 | TLR3 (poly I:C adjuvant)Biologic (subtype unspecified) | Solid Tumors Advanced Solid Tumors |
Upcoming events
No upcoming trial completions or earnings dates on record for this company's assets.
Regulatory and conference events
(2)
Filings, regulator decisions, scientific presentations, topline results and licensing deals, each from a dated source. When a source gives only the month, the month is shown.
Recent
PK, DRAP · LakeShore Biopharma · Source ↗
9 April 2024Topline resultPIKA Rabies VaccinePivotal Phase 3 interim analysis meets primary endpoints
YS Biopharma (now LakeShore Biopharma) · Source ↗